Inhibitor of VEGFR2, c-Met, and RET used to treat medullary thyroid cancer. It induces apoptosis and inhibits cell growth in cancer cells and suppresses proliferation of osteoclasts. (C003B-256077)

Catalog No.: C003B-256077
Mfr. No.: C0006-250 mg
Mfr. Name: LKT Laboratories, Inc
Qty/UOM: 1
UOM: EA

Price: $1,378.65

List Price: $1,531.83

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Cabozantanib is an anticancer chemotherapeutic compound that has been approved to treat medullary thyroid cancer and is in clinical trials as a treatment for other types of solid tumors. Cabozantanib exerts its anticancer activity through inhibition of Met, RET, and VEGFR2, increasing apoptosis and inhibiting cell growth and osteoclast proliferation in vitro and in vivo. Grades: ≥98%

UPC:: 51111779
Condition:: New
Availability:: 3 Days
Weight:: 1.00 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: C0006-250 mg
CAS:: 849217-68-1

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."